MalarVx
MalarVx is a Seattle-based clinical-stage biopharmaceutical company developing malaria vaccines that combine self-amplifying RNA, lipid nanocarriers, and in vitro cultured attenuated parasites to prevent P. falciparum and P. vivax infection in endemic regions.
- Company typePrivate
- Founded2012
- HeadquartersSeattle, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What MalarVx does
MalarVx, Inc. is a privately-held, clinical-stage biopharmaceutical company founded in 2012 and headquartered in Seattle, Washington. The company develops malaria vaccines targeting both Plasmodium falciparum and Plasmodium vivax using two integrated technology platforms: (1) a self-amplifying replicon RNA (repRNA) delivered via HDT Bio's LION lipid nanocarrier, licensed in June 2025, and (2) whole-organism attenuated parasites (radiation-attenuated sporozoites and genetically-attenuated parasites) produced through a proprietary in vitro culture system that grows sporozoites without mosquitoes using a 3D AlgiMatrix scaffold. Its lead approach is a heterologous 'prime-and-trap' regimen combining a repRNA-LION prime with a radiation-attenuated sporozoite trap, designed for same-day administration, reduced cold-chain requirements, and potential multi-species coverage.
The company reports preclinical sterile protection of 80–100%, materially higher than the ~39% efficacy of WHO-approved RTS,S. MalarVx is pre-revenue, funded historically by a single disclosed $110,000 equity round in January 2015 plus ongoing grants from the National Institutes of Health and the U.S. Department of Defense, and operates with a lean team of approximately 6–10 people. Its commercial model contemplates future one-time product sales (and/or licensing) to endemic-region governments and global health organizations such as WHO, Gavi, and UNICEF, targeting children under five and pregnant women in resource-limited malaria-endemic settings where roughly 597,000 deaths and 263 million cases were reported in 2023.
MalarVx firmographics
Firmographics- Name
- MalarVx
- Legal name
- MalarVx, Inc.
- Website
- https://malarvx.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- MalarVx is a Seattle-based clinical-stage biopharmaceutical company developing malaria vaccines that combine self-amplifying RNA, lipid nanocarriers, and in vitro cultured attenuated parasites to prevent P. falciparum and P. vivax infection in endemic regions.
- Ownership category
- akta.pro rank
MalarVx industry classification
Industry- Product category
- Malaria Vaccines
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)
- akta.pro secondary industries
- Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC), Pandemic Preparedness & Rapid-Response Vaccines (HLAIAEAF)
Keywords
Where MalarVx is headquartered
LocationHeadquarters
- HQ city
- Seattle
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
MalarVx business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Vaccine Development and Commercialization: Pre-revenue clinical-stage company focused on developing malaria vaccines. Revenue model will be based on vaccine product sales once regulatory approval is obtained. Target markets include endemic region governments, global health organizations, and public health initiatives.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
MalarVx product offering
Product offeringCore offering
MalarVx develops clinical-stage malaria vaccine candidates built on a self-amplifying replicon RNA (repRNA) subunit prime delivered via HDT Bio's LION lipid nanocarrier, combined with radiation- or genetically-attenuated whole Plasmodium falciparum sporozoites as a boost. The pipeline targets both P. falciparum and P. vivax malaria and is supported by a proprietary in vitro sporozoite production platform that eliminates the need for mosquito-based manufacturing.
Product overview
MalarVx is developing a pipeline of malaria vaccine candidates targeting both Plasmodium falciparum and Plasmodium vivax parasites. The company's portfolio includes two technology platforms: (1) repRNA/LION, a self-amplifying RNA vaccine delivered via lipid nanoparticle; and (2) whole organism vaccines using in vitro cultured sporozoites, including radiation-attenuated sporozoites (RAS) and genetically-attenuated parasites (GAP). The Prime-and-Trap approach combines these platforms using a repRNA subunit prime followed by attenuated sporozoite boost to maximize protective immunity.
Differentiator
Problem solved
Functional benefit
Products and services
- Prime-and-Trap Malaria Vaccine A heterologous prime-boost malaria vaccination strategy that combines a repRNA-based CSP subunit vaccine (delivered via LION nanocarrier) as the prime with radiation-attenuated sporozoites (RAS) as the trap/boost, designed to engage both humoral and cellular immunity against Plasmodium falciparum for endemic-region use.
- repRNA/LION Malaria Vaccine A self-amplifying replicon RNA (repRNA) vaccine candidate delivered via HDT Bio's LION (Lipid InOrganic Nanoparticle) nanocarrier system, designed to induce immune protection against Plasmodium falciparum with enhanced thermal stability (4°C up to one year; room temperature for several days).
- In Vitro Cultured Sporozoites (RAS / GAP whole-parasite vaccine)
Quantifiable outcome
- 80-100% sterile protection in preclinical studies
- +1 more outcomes
Companies that use MalarVx
Customer profileSegments2 records
Ideal customer profiles1 record
MalarVx technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
MalarVx partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- HDT BiocoreMalarVx licensed HDT Bio's proprietary self-amplifying replicon RNA (repRNA) and lipid nanoparticle (LION) technologies for use in malaria vaccines. HDT Bio is a Seattle-based clinical-stage biopharmaceutical company specializing in advanced RNA vaccine technologies. The agreement provides MalarVx additional support from HDT to develop and commercialize malaria vaccines. HDT Bio's LION platform has demonstrated ability to rapidly generate potent, durable immune responses with favorable safety profile. This expands the long-standing relationship between the parties.
- Oregon Health Sciences University (OHSU)coreCollaboration with Dr. Brandon Wilder's malaria research program at OHSU (formerly at NAMRU-6 in Lima, Peru). Dr. Wilder serves on MalarVx's Advisory Board.
- University of WashingtoncoreCollaboration with Dr. Sean Murphy and Dr. Melanie Sears at University of Washington, Seattle WA, for cellular immunity analysis.
- Bloodworks NWminorHistorical collaboration with Bloodworks NW, Seattle WA, for blood and blood products used for culturing Plasmodium parasites.
- Walter Reed Army Institute of Research (WRAIR)minorHistorical collaboration with WRAIR in Maryland DC for malaria research.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
MalarVx competitors and assessment
Company assessmentOthers
- HDT Bio: HDT Bio is the licensor of the repRNA and LION nanoparticle technology underpinning MalarVx's vaccine; it is also an independent RNA vaccine developer with overlapping platform technology and potential pipeline overlap.
- PATH Malaria Vaccine Initiative: PATH's MVI is a global health product development partnership that funds and supports advanced malaria vaccine candidates; it is a likely funding, partnership, and procurement intermediary for MalarVx.
- Walter Reed Army Institute of Research (WRAIR): WRAIR is a historical MalarVx collaborator and an independent developer of malaria vaccines (including whole sporozoite approaches); it represents both a partnership opportunity and an institutional competitor for U.S. DoD malaria funding.
Direct peers
- Sanaria Inc. Sanaria develops radiation-attenuated sporozoite (PfSPZ) malaria vaccines—the same whole-organism approach that anchors MalarVx's prime-and-trap regimen. They compete directly for global health procurement and clinical-trial partnerships.
- GSK (RTS,S/Mosquirix): GSK developed RTS,S/Mosquirix, the first WHO-recommended malaria vaccine, targeting the same P. falciparum market and global health customer base that MalarVx ultimately serves.
- Bharat Biotech (R21/Matrix-M): Bharat Biotech co-developed R21/Matrix-M with the Jenner Institute; WHO-recommended in 2023, it is rapidly scaling and competing directly with MalarVx's target market of endemic-country immunization programs.
Emerging players
- BioNTech: BioNTech is developing an mRNA-based malaria vaccine candidate (BNT165) using the same RNA vaccine modality that underpins MalarVx's repRNA prime; it represents a much larger, well-capitalized competitor pursuing the same next-generation malaria vaccine opportunity.
- Moderna: Moderna's mRNA platform includes a malaria vaccine program (mRNA-6930) that competes in the same nucleic-acid vaccine category as MalarVx's repRNA-LION product.
- Jenner Institute (University of Oxford): The Jenner Institute co-developed R21/Matrix-M and remains one of the leading malaria vaccinology groups, competing for talent, grant funding, and clinical-trial sites that MalarVx also needs.
Broad incumbents
- Novavax: Novavax is a larger recombinant protein vaccine platform company whose Matrix-M adjuvant is used in R21; while not focused on malaria, its adjuvant franchise positions it as an enabling technology supplier in the same disease area.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks7 records
Key highlights7 records
Customer concentration
MalarVx social profiles
Digital presenceMalarVx financial estimates
Financial estimateRevenue estimate
Valuation estimate
MalarVx leadership team
Management profileNumber of profiles
Profiles7 records
MalarVx funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MalarVx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MalarVx
What does MalarVx do?
MalarVx develops clinical-stage malaria vaccine candidates built on a self-amplifying replicon RNA (repRNA) subunit prime delivered via HDT Bio's LION lipid nanocarrier, combined with radiation- or genetically-attenuated whole Plasmodium falciparum sporozoites as a boost. The pipeline targets both P. falciparum and P. vivax malaria and is supported by a proprietary in vitro sporozoite production platform that eliminates the need for mosquito-based manufacturing.
Is MalarVx a public or private company?
MalarVx is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was MalarVx founded?
MalarVx was founded in 2012. It employs 1 to 10 people.
Where is MalarVx based?
MalarVx is headquartered in Seattle, United States, in the North America region.
How does MalarVx make money?
One revenue line is on record: vaccine Development and Commercialization.
Who are MalarVx's main competitors?
Others on record are HDT Bio, PATH Malaria Vaccine Initiative and Walter Reed Army Institute of Research (WRAIR). Direct peers are Sanaria Inc., GSK (RTS,S/Mosquirix) and Bharat Biotech (R21/Matrix-M). Emerging players are BioNTech, Moderna and Jenner Institute (University of Oxford). Novavax is listed as a broad incumbent.
Does MalarVx have an API?
No public API is recorded for MalarVx.
What industry is MalarVx in?
MalarVx's product category is Malaria Vaccines. Its primary akta.pro industry code is HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA), with a secondary code of HLAAAEAC, Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens). Its NAICS code is 325414 and its SIC code is 2836.